If a prospective analysis confirms the reliability of the test in general and the cut-point for positive staining tumor nuclei described here (>50% tumor nuclei positive for MYC), MYC IHC will be implemented as a screening test for deciding which cases of DLBCL we will further analyze by FISH in daily practice. The gene discussed is MYC; the disease is neoplasm.